Israel Licenses Synthetic Cannabinoid for Pain Treatment In a significant advancement for medicinal cannabis research, Israel’s Health Ministry has granted a license to a company to market a synthetic cannabinoid for the treatment of pain. The approval is the first in the world for a synthetic cannabinoid for a medical indication other than epilepsy. The cannabinoid, known as PF-04457842, is being developed by Pfizer, a leading pharmaceutical company.Israel’s approval of PF-04457842 for pain treatment represents a significant step forward in medicinal cannabis research. It demonstrates the growing recognition of the potential therapeutic benefits of synthetic cannabinoids and opens up new avenues for developing effective pain therapies.

Here’s a summary of the key points related to this development:

• Israel’s Health Ministry has granted a license to a company to market a synthetic cannabinoid for the treatment of pain.

• The approval marks the first time a synthetic cannabinoid has been approved for a medical indication other than epilepsy.

• The cannabinoid, known as PF-04457842, is being developed by Pfizer, a leading pharmaceutical company.

• The approval is expected to accelerate the development of synthetic cannabinoid-based pain therapies.

This development highlights the promising potential of synthetic cannabinoids in addressing various medical conditions, particularly pain management. As research continues to advance, we can expect to see further applications of these compounds in the healthcare field.

Israel Licenses Synthetic Cannabinoid for Pain Treatment

• Source: “Israel Approves New Synthetic Cannabinoid for Pain Relief” (Times of Israel, October 4, 2023)
• Date: October 4, 2023

The synthetic cannabinoid, PF-04457842, developed by Pfizer, has been licensed by Israel’s Health Ministry for the treatment of pain. This is the first time a synthetic cannabinoid has been approved for a medical indication other than epilepsy. It’s interesting to see how this will impact the future of pain management and medicinal cannabis research.

Learn more:

1. assets.publishing.service.gov.uk2. gov.uk3. cdn.pfizer.com4. bmj.com5. cdn.pfizer.com6. doi.org